Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €91.89 EUR
Change Today +0.69 / 0.76%
Volume 4.4K
NOT On Other Exchanges
Symbol
Exchange
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 5:01 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-reg (NOT) Snapshot

Open
€91.08
Previous Close
€91.20
Day High
€92.15
Day Low
€91.03
52 Week High
03/24/15 - €94.98
52 Week Low
03/27/14 - €58.83
Market Cap
248.2B
Average Volume 10 Days
35.7K
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
03/3/15
P/E TM
--
Dividend
€2.53
Dividend Yield
2.62%
Current Stock Chart for NOVARTIS AG-REG (NOT)

novartis ag-reg (NOT) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

133,413 Employees
Last Reported Date: 01/27/15
Founded in 1895

novartis ag-reg (NOT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.6.1M
Chief Financial Officer
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-reg (NOT) Key Developments

Novartis Announces Encouraging Two-Year Data from Psoriasis Study

Novartis has announced new two-year data from the extension study of the pivotal Phase III FIXTURE and ERASURE trials demonstrating sustained efficacy with Cosentyx with an acceptable safety profile for the treatment of psoriasis patients. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients. In this extension of the FIXTURE and ERASURE studies, 995 patients who achieved Psoriasis Area Severity Index (PASI) 75 response after a year of therapy (Week 52) received either Cosentyx 300 mg, Cosentyx 150 mg or placebo for an additional year (Week 104). After two full years of therapy, 7 out of 10 (70.6%) patients treated with Cosentyx 300 mg had clear to almost clear skin (PASI 90); 4 out of 10 (43.9%) had clear skin (PASI 100) and almost 9 out of 10 (88.2%) patients maintained their PASI 75 response at Week 104. For patients treated with Cosentyx 150 mg, 44.6% had clear or almost clear skin (PASI 90); 23.5% had clear skin (PASI 100) and 75.5% maintained their PASI 75 response at Week 104. PASI assesses treatment efficacy by measuring the reduction in redness, scaling and thickness of psoriatic plaques and the extent of involvement in each region of the body.

Sandoz Ltd. Wins GBP 220.9 Million Multiple Awardees Contract for Supplying Proprietary Pharmaceuticals

Sandoz Ltd. won a GBP 220.9 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 057-099494).

Novartis AG Presents Cosentyx(TM) Two Year Efficacy And Safety Data

Novartis announced new two-year results demonstrating sustained efficacy with Cosentyx(TM) (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. Results were presented for the first time in a late-breaking session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients. In this extension of the FIXTURE and ERASURE studies, 995 patients who achieved Psoriasis Area Severity Index (PASI) 75 response after a year of therapy (Week 52) received either Cosentyx 300 mg, Cosentyx 150 mg or placebo for an additional year (Week 104). After two full years of therapy, 7 out of 10 (70.6%) patients treated with Cosentyx 300 mg had clear to almost clear skin (PASI 90); 4 out of 10 (43.9%) had clear skin (PASI 100) and almost 9 out of 10 (88.2%) patients maintained their PASI 75 response at Week 104. For patients treated with Cosentyx 150 mg, 44.6% had clear or almost clear skin (PASI 90); 23.5% had clear skin (PASI 100) and 75.5% maintained their PASI 75 response at Week 104. PASI assesses treatment efficacy by measuring the reduction in redness, scaling and thickness of psoriatic plaques and the extent of involvement in each region of the body. In the study, 94.8% of patients who initially received placebo (at the start of the extension) and were switched to receive Cosentyx 300 mg after relapse, were able to achieve PASI 75 and 70.3% achieved PASI 90 within 12 weeks of re-starting Cosentyx treatment. Cosentyx demonstrated an acceptable safety profile. The most common adverse events (AEs) for the 300 mg and 150 mg treatment arms were nasopharyngitis (24.1% and 17.0%, respectively), upper respiratory tract infection (5.3% and 5.0%), hypertension (4.3% and 5.2%), headache (5.6% and 2.9%) and arthralgia (4.0% and 4.2%). Infections and infestations were reported in 53.1% of patients receiving Cosentyx 300 mg and 41.6% of patients receiving 150 mg. There were 64 (6.0%) serious AEs (SAEs) in any Cosentyx dose and no deaths reported during the study. Patients who had been receiving Cosentyx 300 mg or 150 mg during the maintenance period of the core studies, and who exhibited a PASI 75 response at Week 52 of the core studies, were randomized to continue the same Cosentyx dose or receive placebo. Patients who exhibited partial response (PASI 50 to (PASI 75 response) from baseline at Week 52 of the core studies were also eligible to enter A2302E, but did not enter the randomized withdrawal extension study. Partial responders instead continued the same treatment dose (Cosentyx 300 mg or 150 mg) that they received at the time of completing the maintenance period (Week 52) in the core studies. Non-responders (patients who did not achieve at least a PASI 50 response at Week 52 of the core study) were not eligible to enter any part of this extension study. During the extension study, patients randomized to placebo and who experienced relapse (defined as loss of)50% of the maximum PASI gain compared to baseline of the core study) at any study visit received Cosentyx 300 mg or 150 mg, respectively, once weekly for 4 weeks, followed by Cosentyx dosing every 4 weeks thereafter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOT:GR €91.89 EUR +0.69

NOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $101.08 USD +1.22
Johnson & Johnson $100.14 USD -0.20
Merck & Co Inc $57.60 USD -0.66
Pfizer Inc $34.16 USD -0.14
Roche Holding AG SFr.265.20 CHF +1.30
View Industry Companies
 

Industry Analysis

NOT

Industry Average

Valuation NOT Industry Range
Price/Earnings 23.4x
Price/Sales 4.5x
Price/Book 3.4x
Price/Cash Flow 26.7x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.